Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 422 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Distress Respiratory Syndrome Clear all
Withdrawn No phase listed Observational

Genetic Variability and Biomarkers in Children With Acute Lung Injury

NCT01048996
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Weeks to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 21, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional

SILtuximab in Viral ARds (SILVAR) Study

NCT04616586
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
Interventions
Siltuximab, Normal Saline
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
12 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Results available

Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study

NCT00296231
View directory record Official record
Conditions
Infant Respiratory Distress Syndrome, Respiratory Insufficiency, Apnea of Prematurity
Interventions
Nasal high frequency ventilation
Other
Lead sponsor
Tarah T Colaizy
Other
Eligibility
7 Days to 3 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset

NCT04729075
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
ARDS and COVID19 treatments
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)

NCT04383730
View directory record Official record
Conditions
Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
Interventions
Intravenous sedation, Inhaled sedation
Drug
Lead sponsor
University Hospital, Clermont-Ferrand
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 21, 2026, 2:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Long COVID-19 Intervention Using Digital Health & Technology

NCT05616806
View directory record Official record
Conditions
Long COVID, Distress Tolerance
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

NCT06402318
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions
A&M Breathalyzer PROTECT Kiosk
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

NCT04565249
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, SARS-CoV-2
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

suPAR Michigan M2C2 Heterogeneity Validation Cohort Study

NCT07466524
View directory record Official record
Conditions
COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
Interventions
suPARnostic® TurbiLatex Assay on Roche cobas c501
Diagnostic Test
Lead sponsor
ViroGates A/S
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Not listed Early Phase 1 Interventional

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

NCT06249633
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Pulmonary Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Yuri Matusov
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

NCT01220687
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infants, Very Low Birth Weight Baby
Interventions
iNO, Nitrogen
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Minute to 2 Minutes
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

NCT06701682
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional

The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study

NCT00739115
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Heliox gas
Other
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Minute to 12 Hours
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Not applicable Interventional Results available

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NCT04382391
View directory record Official record
Conditions
COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions
gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 21, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Results available

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

NCT01438853
View directory record Official record
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
TNX-832, Placebo
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Enrolling by invitation No phase listed Observational

The Medical Management in Patients Exposed to Weapons of Mass Destruction

NCT05026645
View directory record Official record
Conditions
Chemical Injury, Chemicals; Intoxication, Acute Respiratory Distress Syndrome, Distress Respiratory Syndrome, Medical Emergencies
Interventions
Clinical interventions performed in acute settings (contaminated environment), Protection (clinician and patient), Decontamination (clinician and patient)
Procedure
Lead sponsor
St. Justine's Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2036
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Not yet recruiting Not applicable Interventional

Trial of Total Lung Protective Ventilation in Adult VV-ECMO Patients With Severe ARDS

NCT07790133
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome), VV ECMO
Interventions
Mechanical Power Targeted Ventilation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

NCT03969992
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant
Interventions
AeroFact, nCPAP
Drug · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
26 Weeks to 31 Weeks
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Not listed No phase listed Observational

Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study

NCT01806532
View directory record Official record
Conditions
Respiratory Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Vitamin D to Improve Outcomes by Leveraging Early Treatment

NCT03096314
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
47
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 2:42 AM EDT